vialroom
Fortnightly digest · 2024-01-29 → 2024-02-11

two new channels and an amylin that will not behave like sema

Two channels opened this fortnight, which for a room this size counts as expansion. The amylin channel immediately had to spend a week explaining that an amylin analogue is not a GLP-1 agonist and cannot be titrated as though it were. The Asia channel opened with a member in Singapore explaining what an entirely legitimate route actually costs.

294messages
19day logs
4channels noted
5notes

What happened

  • The cagrilintide channel opened and the cagrilintide Phase 2 result in Lancet 2021 was the first thing pinned into the conversation.
  • Several members had been running an amylin on a semaglutide ladder and reporting nausea they had assumed was unavoidable rather than iatrogenic pacing.
  • The Asia channel established its founding lesson within a day: being physically nearer the manufacturers makes nothing simpler and often makes customs worse.
  • WuXi TIDES was discussed as a synthesis house rather than a shop, and the difference in risk profile got explained twice.
  • A newcomer asked for a semaglutide-to-cagrilintide conversion and was told, correctly, that no such number exists.

Channels this fortnight

Most-reacted messages in this fortnight

Pulled from the logs, not hand-picked. Each links to the exact message.

Busiest logs in this fortnight

Topics touched